

# Clinical trials of statins for heart failure in all type of patients

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 statins

Trial	Treatments	Patients	Trials design and methods
<b>atorvastatin vs control</b>			
Wojnicz , 2006 n=36/38 follow-up: 6 months	atorvastatin 40 mg/day versus conventional treatment for heart failure	patients with inflammatory dilated cardiomyopathy (DC) (positive immunohistochemistry results on endomyocardial biopsy)	Parallel groups open
Yamada , 2007 n=19/19 follow-up: mean 2.58y	atorvastatin 10 mg/d versus standard treatment	outpatients with mild to moderate CHF and radionuclide left ventricular ejection fraction (LVEF) <40%	Parallel groups
<b>simvastatin vs control</b>			
Hong , 2005 n=106/96 follow-up: 1 year	simvastatin versus no treatment	patients with ischemic heart failure who underwent percutaneous coronary intervention (PCI) for acute myocardial infarction (left ventricular [LV] ejection fraction <40% )	Parallel groups open
<b>atorvastatin vs placebo</b>			
Sola , 2006 n=54/54 follow-up: 1y	atorvastatin 20 mg/day versus placebo	patients with nonischemic HF and a left ventricular ejection fraction (LVEF) <=35%	Parallel groups double blind
Strey , 2005 n=24/24 follow-up: 6 weeks	atorvastatin 40mg versus placebo	patients with stable, symptomatic heart failure (New York Heart Association Class II or III) and a left ventricular ejection fraction <40%	Cross over
<b>cerivastatin vs placebo</b>			
Laufs , 2004 n=8/7 follow-up: mean 20 weeks	cerivastatin 0.4 mg versus placebo	patients with heart failure NYHA II-III caused by non-ischemic dilated cardiomyopathy	Parallel groups double blind
<b>rosuvastatin vs placebo</b>			
CORONA , 2007 [NCT00206310] n=2514/2497 follow-up: 32.9 months median	rosuvastatin 10mg/d versus placebo	patients at least 60 years of age with NYHA class II, III, or IV ischemic, systolic heart failure	Parallel groups double blind
Krum , 2007 n=40/46 follow-up: 6 months	rosuvastatine 40mg/d versus placebo	patients with systolic (LVEF<40% ) CHF of ischemic or nonischemic etiology	Parallel groups double blind Australia

continued...

Trial	Treatments	Patients	Trials design and methods
<b>GISSI-HF rosuvastatine , 2008</b> [NCT00336336] n=2314/2317 follow-up: 3.9y median (IQR 3-4.4)	low-dose rosuvastatin 10 mg daily versus placebo	Patients with NYHA classes II to IV heart failure, whatever the cause and the LVEF and already receiving optimized recommended therapy with no clear indication or contraindication to cholesterol-lowering therapy	Parallel groups double blind Italy
<b>simvastatin vs placebo</b>			
<b>Node , 2003</b> n=24/27 follow-up:	simvastatin 10mg/d versus placebo	patients with symptomatic, nonischemic, dilated cardiomyopathy	
<b>simvastatin vs ezetimibe</b>			
<b>Landmesser , 2005</b> n=10/10 follow-up:	simvastatin 10mg/d versus ezetimibe 10mg/d	patients with chronic heart failure	

## References

### Wojnicz, 2006:

Wojnicz R, Wilczek K, Nowalany-Kozielska E, Szygula-Jurkiewicz B, Nowak J, Polonski L, Dyrbus K, Badzinski A, Mercik G, Zembala M, Wodniecki J, Rozek MM Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. *Am J Cardiol* 2006;97:899-904 [16516598]

### Yamada, 2007:

Yamada T, Node K, Mine T, Morita T, Kioka H, Tsukamoto Y, Tamaki S, Masuda M, Okuda K, Fukunami M Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. *Am Heart J* 2007;153:1055.e1-8 [17540209]

### Hong, 2005:

Hong YJ, Jeong MH, Hyun DW, Hur SH, Kim KB, Kim W, Lim SY, Lee SH, Hong SN, Kang DG, Yun KH, Kim KH, Lee YS, Park HW, Kim JH, Ahn YK, Cho JG, Park JC, Kang JC Prognostic significance of simvastatin therapy in patients with ischemic heart failure who underwent percutaneous coronary intervention for acute myocardial infarction. *Am J Cardiol* 2005;95:619-22 [15721103]

### Sola, 2006:

Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. *J Am Coll Cardiol* 2006;47:332-7 [16412856]

### Strey, 2005:

Strey CH, Young JM, Molyneux SL, George PM, Florkowski CM, Scott RS, Frampton CM Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. *Atherosclerosis* 2005;179:201-6 [15721028]

### Laufs, 2004:

Laufs U, Wassmann S, Schackmann S, Heeschen C, Bhm M, Nickenig G Beneficial effects of statins in patients with non-ischemic heart failure. *Z Kardiol* 2004;93:103-8 [14963675]

### CORONA, 2007:

Kjekshus J, Apetrei E, Barrios V, Bhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jnosi A, Kamensk G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberg Rosuvastatin in older patients with systolic heart failure. *N Engl J Med* 2007;357:2248-61 [17984166]

### Krum, 2007:

Krum H, Ashton E, Reid C, Kalff V, Rogers J, Amarena J, Singh B, Tonkin A Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. *J Card Fail* 2007;13:1-7 [17338996]

**GISSI-HF rosuvastatine, 2008:**

Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R, Nicolosi GL, Porcu M Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. *Eur J Heart Fail* 2004 Aug;6:635-41 [[15302013](#)]

Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet* 2008;372:1231-9 [[18757089](#)]

**Node, 2003:**

Node K, Fujita M, Kitakaze M, Hori M, Liao JK Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. *Circulation* 2003;108:839-43 [[12885745](#)]

**Landmesser, 2005:**

Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, Manes C, Fischer D, de Groot K, Fliser D, Fauler G, Mrz W, Drexler H Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. *Circulation* 2005;111:2356-63 [[15867181](#)]

## 2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.